Lipocine (STU:2VT0) Stock Based Compensation: €0.20 Mil (TTM As of Mar. 2026)


STU:2VT0 Lipocine Inc STU:2VT0
50 GF Score
Price €3.94
GF Value €3.01
! 4 Warning Signs
View Full Analysis

What is Lipocine Stock Based Compensation?

Lipocine STU:2VT0 50 Stock Based Compensation is €0.20 Mil as of Mar. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 50/100 and a GF Value™ of €3.01. The stock has 4 warning signs investors should review.

Lipocine's Stock Based Compensation for the three months ended in Mar. 2026 was €0.06 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.20 Mil.

Lipocine Stock Based Compensation Related Terms

Lipocine Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Lipocine's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Stock Based Compensation Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.60 0.60 0.39 0.21

Lipocine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.05 0.05 0.06
STU:2VT0
50GF Score
Lipocine Inc STU:2VT0
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipocine Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.20 Mil.

What does a Stock Based Compensation of €0.20 Mil mean?
Lipocine (STU:2VT0) has a Stock Based Compensation of €0.20 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Lipocine and its competitors.
Is Lipocine's Stock Based Compensation too high?
Lipocine's current Stock Based Compensation is €0.20 Mil. Overall, Lipocine has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Stock Based Compensation compare to NCEL and PTN?
Lipocine's Stock Based Compensation of €0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Lipocine and its competitors. Lipocine's current Stock Based Compensation is €0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Stock Based Compensation of €0.20 Mil. The stock's GF Value™ is €3.01, compared to a current price of €3.94 — trading 31% above its estimated fair value. The current Stock Based Compensation is €0.20 Mil. Lipocine's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Stock Based Compensation is €0.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 31% above its estimated GF Value™ of €3.01.

Key valuation signals for STU:2VT0:

  • Stock Based Compensation: €0.20 Mil
  • GF Value™: €3.01 vs. price of €3.94 (31% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lipocine Business Description

Other Exchanges LPCN:USA
Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
50GF Score

Get the complete analysis for STU:2VT0

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€3.01
GF Value